Data Integrity and Antibiotic Clinical Trials: FDA, Industry Try Systemic Therapy
This article was originally published in RPM Report
Executive Summary
FDA's push to encourage development of new antibiotics requires getting past data integrity issues in the class. The agency's workshop on antibacterial clinical trials revealed a range of efforts aimed at better Good Clinical Practices compliance - and those efforts can just as easily be applied to other drug classes